Changes in BeOne Medicines executive stock ownership
Between November 5 and November 9, 2026, BeOne Medicines Ltd. executives conducted several stock transactions, including sales and gifts of securities. These transactions are detailed in reports filed with the Securities and Exchange Commission (SEC) during this period.
Key points
- Chan Lee, senior vice president and general counsel, sold 1,115 shares on November 5, 2026.
- Xiaodong Wang, director and chair of the scientific advisory board, gifted 1,183 shares on November 9, 2026.
- Open-market insider sales can lead observers to make various assumptions about the company's future performance.
Executives sold shares in market transactions
Chan Lee, senior vice president and general counsel, sold 1,115 shares on November 5, 2026. The sale was executed under a Rule 10b5-1 trading plan, a preset selling schedule executives set up in advance.
Titus Benjamin Ball, principal accounting officer, exercised options for 1,559 shares on November 6, 2026. He sold all 1,559 shares on the open market the same day.
Value of shares sold, by insider
Other securities transactions
Xiaodong Wang, director and chair of the scientific advisory board, gifted 1,183 shares on November 9, 2026. Following this transaction, he held 4,586,930 shares.
Risks and assumptions
Open-market insider sales can lead observers to make various assumptions about the company's future performance. However, the filings themselves do not state the reasons or strategic goals behind these sales, except for the existence of one executive's trading plan.
What to watch
Investors should monitor future insider transaction reports published on the SEC website to track changes in stock ownership by key company personnel.
Original sources
- 144 filing, November 5, 2026
- 144 filing, November 6, 2026
- 4 filing, November 9, 2026
- 4 filing, November 10, 2026
- 4 filing, November 12, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow BeOne Medicines
A notification in your browser or on your phone when we publish about BeOne Medicines. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
